Virus GLP Production

Summary of Production of the GMP Challenge Stock. According to the latest cell gene therapy research, Creative Biolabs provides the GLP virus production platform for cancer treatment, including the TCR design and CAR design process systems. As a leading market forefront cell therapy company, we design a huge carrier construction of laboratory with strict operation procedures, and we are devoted to offering the most convenient and efficient technical services to help you achieve your scientific research goal.

GLP Standard Laboratory Platform

In order to ensure the safety of your virus products, we’ve made great efforts to establish GLP standard laboratory, and are capable of providing production services and QC tests through a standardization process. Each step has a strict SOP specification operating system, including:

Summary of Production of the GMP Challenge Stock. Fig.1 Summary of Production of the GMP Challenge Stock.

Virus GLP Vector Platform

The vector production facility produces lentivirus and retrovirus vectors in a sterile room, which is compliant with FDA's Current Good Laboratory Practice (GLP) and is used to produce viral vectors that support early clinical trials.

Creative Biolabs has many viral vectors that can be transformed into a conditionally replicative oncolytic virus with oncolytic activity by molecular biology, including:

√  Adenovirus vector
√  Retrovirus vector
√  Herpes simplex virus vector
√  Vaccinia virus vector

Highlights

Creative Biolabs has established advanced and first-class facilities, such as molecular biology laboratory, the cytology laboratory and the virology laboratory, with larger production scale and more diversified production capacity, which enables a variety of suspension and adhesion production platforms to be created. If there is any interest in our novel oncolytic treatment services, just contact us and obtain more information.

Reference

  1. Fullen D J; et al. Accelerating influenza research: vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type h3n2 virus for the human viral challenge model[J]. PLOS ONE, 2016, 11(6): e0157211.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.